|
|
Article: Inspire Pharmaceuticals Provides Update on Allergic Rhinitis Program; Enrollment Complete in First Phase III Trial; Phase II Data to be Presented at AAAAI Meeting.
- Article from:
- PR Newswire
- Article date:
- March 6, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Inspire Pharmaceuticals, Inc. today announced that enrollment is complete in a 630-patient multi-center clinical trial of INS37217 Intranasal in patients with perennial allergic rhinitis (PAR). The trial is a 28-day, randomized, parallel-group, double-blind study designed to evaluate the safety and efficacy of INS37217 Intranasal in a non-preserved nasal spray formulation, compared to placebo. Inspire expects to release top-line results from the study by the end of the second quarter of 2003. At that time, the Company plans to request a meeting with the Food and Drug Administration to discuss the future development program for INS37217 Intranasal, including the ...